190 related articles for article (PubMed ID: 21595596)
1. Ofatumumab in the treatment of low-grade non-Hodgkin's lymphomas and chronic lymphocytic leukemia.
Bello C; Veliz M; Pinilla-Ibarz J
Expert Rev Clin Immunol; 2011 May; 7(3):295-300. PubMed ID: 21595596
[TBL] [Abstract][Full Text] [Related]
2. Ofatumumab in the treatment of non-Hodgkin's lymphomas.
Karlin L; Coiffier B
Expert Opin Biol Ther; 2015 Jul; 15(7):1085-91. PubMed ID: 26043777
[TBL] [Abstract][Full Text] [Related]
3. Ofatumumab: a novel anti-CD20 monoclonal antibody for treatment of refractory chronic lymphocytic leukemia.
Nightingale G
Ann Pharmacother; 2011 Oct; 45(10):1248-55. PubMed ID: 21896924
[TBL] [Abstract][Full Text] [Related]
4. Ofatumumab for newly diagnosed and relapsed/refractory chronic lymphocytic leukemia.
Reagan JL; Castillo JJ
Expert Rev Anticancer Ther; 2011 Feb; 11(2):151-60. PubMed ID: 21342032
[TBL] [Abstract][Full Text] [Related]
5. Ofatumumab as front-line therapy in untreated chronic lymphocytic leukemia.
Reagan JL; Castillo JJ
Future Oncol; 2014 May; 10(7):1147-55. PubMed ID: 24947256
[TBL] [Abstract][Full Text] [Related]
6. Ofatumumab for the treatment of chronic lymphocytic leukaemia in patients who are refractory to fludarabine and alemtuzumab: a critique of the submission from GSK.
Hoyle M; Crathorne L; Garside R; Hyde C
Health Technol Assess; 2011 May; 15 Suppl 1():61-7. PubMed ID: 21609654
[TBL] [Abstract][Full Text] [Related]
7. Ofatumumab, a novel anti-CD20 monoclonal antibody for the treatment of B-cell malignancies.
Cheson BD
J Clin Oncol; 2010 Jul; 28(21):3525-30. PubMed ID: 20458041
[TBL] [Abstract][Full Text] [Related]
8. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab.
Lemery SJ; Zhang J; Rothmann MD; Yang J; Earp J; Zhao H; McDougal A; Pilaro A; Chiang R; Gootenberg JE; Keegan P; Pazdur R
Clin Cancer Res; 2010 Sep; 16(17):4331-8. PubMed ID: 20601446
[TBL] [Abstract][Full Text] [Related]
9. Novel biologic agents for non-Hodgkin lymphoma and chronic lymphocytic leukemia-part 1.
Siddiqi T; Rosen ST
Oncology (Williston Park); 2015 Mar; 29(3):198-203. PubMed ID: 25772456
[TBL] [Abstract][Full Text] [Related]
10. The future of CD20 monoclonal antibody therapy in B-cell malignancies.
Czuczman MS; Gregory SA
Leuk Lymphoma; 2010 Jun; 51(6):983-94. PubMed ID: 20367564
[TBL] [Abstract][Full Text] [Related]
11. Ofatumumab for the treatment of chronic lymphocytic leukemia.
Grosicki S
Expert Rev Hematol; 2015 Jun; 8(3):265-72. PubMed ID: 25882470
[TBL] [Abstract][Full Text] [Related]
12. Role of ofatumumab in treatment of chronic lymphocytic leukemia.
Veliz M; Pinilla-Ibarz J
J Blood Med; 2011; 2():71-7. PubMed ID: 22287865
[TBL] [Abstract][Full Text] [Related]
13. [Fludarabine in the treatment of chronic lymphocytic leukemia and other lymphoproliferative disorders].
Pawelski S
Acta Haematol Pol; 1995; 26(3):263-8. PubMed ID: 8525771
[TBL] [Abstract][Full Text] [Related]
14. What is the status of novel anti-CD20 antibodies for chronic lymphocytic leukemia and are they set to leave rituximab in the shadows?
Chaudhry M; Cheson BD
Expert Rev Hematol; 2015 Dec; 8(6):733-42. PubMed ID: 26368831
[TBL] [Abstract][Full Text] [Related]
15. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
Milani C; Castillo J
Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
[TBL] [Abstract][Full Text] [Related]
16. Ofatumumab, a human anti-CD20 monoclonal antibody.
Osterborg A
Expert Opin Biol Ther; 2010 Mar; 10(3):439-49. PubMed ID: 20109133
[TBL] [Abstract][Full Text] [Related]
17. Ofatumumab in poor-prognosis chronic lymphocytic leukemia: a phase IV, non-interventional, observational study from the European Research Initiative on Chronic Lymphocytic Leukemia.
Moreno C; Montillo M; Panayiotidis P; Dimou M; Bloor A; Dupuis J; Schuh A; Norin S; Geisler C; Hillmen P; Doubek M; Trněný M; Obrtlikova P; Laurenti L; Stilgenbauer S; Smolej L; Ghia P; Cymbalista F; Jaeger U; Stamatopoulos K; Stavroyianni N; Carrington P; Zouabi H; Leblond V; Gomez-Garcia JC; Rubio M; Marasca R; Musuraca G; Rigacci L; Farina L; Paolini R; Pospisilova S; Kimby E; Bradley C; Montserrat E
Haematologica; 2015 Apr; 100(4):511-6. PubMed ID: 25596264
[TBL] [Abstract][Full Text] [Related]
18. Ofatumumab for treating chronic lymphocytic leukemia: a safety profile.
Korycka-Wołowiec A; Wołowiec D; Robak T
Expert Opin Drug Saf; 2015; 14(12):1945-59. PubMed ID: 26566719
[TBL] [Abstract][Full Text] [Related]
19. Applications of monoclonal antibodies for the treatment of hematological malignancies.
Migkou M; Dimopoulos MA; Gavriatopoulou M; Terpos E
Expert Opin Biol Ther; 2009 Feb; 9(2):207-20. PubMed ID: 19236251
[TBL] [Abstract][Full Text] [Related]
20. Killing of CLL and NHL cells by rituximab and ofatumumab under limited availability of complement.
Okroj M; Eriksson I; Österborg A; Blom AM
Med Oncol; 2013 Dec; 30(4):759. PubMed ID: 24198205
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]